Skip to main content
SpringerLink
Log in

Amisulpride and Sulpiride in the Treatment of Psychosis

  • Reference work entry
  • First Online:
NeuroPsychopharmacotherapy

Abstract

Amisulpride is a second-generation (atypical) antipsychotic primarily used to treat schizophrenia and bipolar disorder. In low dose it is also used to treat dysthymia. It blocks selectively postsynaptic dopamine D2 and D3 receptors, and in low doses presynaptic receptors. The efficacy in treatment of psychoses was established in randomized, double-blind, placebo-controlled studies and maintenance studies. Some meta-analyses found amisulpride more efficacious compared to other antipsychotics. Common side effects are induced by increase of prolactin level.

Sulpiride is a low-potent antipsychotic drug chemically and clinically similar to amisulpride. It is mainly used in the treatment of dysthymia, depressive disorder, and vertigo.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 949.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,399.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aylward M, Maddock J, Dewland P, Lewis P. Sulpiride in depressive illness. Adv Biol Psychiatr. 1981;7:154–65.

    Google Scholar 

  • Carrière P, Bonhomme D, Lempérière T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry. 2000;15:321–9.

    PubMed  Google Scholar 

  • Cassano G, Castrogiovanni P, Conti L, Bonollo L. Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trail. Curr Ther Res. 1975;17:189–201.

    CAS  PubMed  Google Scholar 

  • Cohen LS, Viguera AC, McInerney KA, Freeman MP, et al. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for atypical antipsychotics. Am J Psychiatry. 2016;173:263–70.

    PubMed  Google Scholar 

  • Colonna L, Guerault E, Turjanski S. Long-term study of amisulpride in the treatment of schizophrenia. Biol Psychiatry. 1997;42:181S.

    Google Scholar 

  • Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol. 2000;15:13–22.

    CAS  PubMed  Google Scholar 

  • Costa E, Silva JA. Comparative doubleblind study of amisulpride versus haloperidol in the treatment of acute psychotic states. In: Borenstein P, editor. Amisulpride. Paris: Expansion Scientifique Francaise; 1989. p. 93–104.

    Google Scholar 

  • Favennec C, Rein W, Turjanski S. The safety profile of amisulpride, an “atypical” antipsychotic. Eur Neuropsychopharmacol. 1996;6:S4–111.

    Google Scholar 

  • Fleurot O, Bech P, Turjanski S. Amisulpride versus risperidone in the treatment of acute schizophrenia. Biol Psychiatry. 1997;42:194S.

    Google Scholar 

  • Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14:2–44.

    PubMed  Google Scholar 

  • Hiemke C, Bergemann N, Clement HW, Conca A, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.

    CAS  PubMed  Google Scholar 

  • Huybrechts KF, Hernández-Díaz S, Patorno E, Desai RJ, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiat. 2016;73:938–46.

    Google Scholar 

  • Johnsen E, Kroken RA, Løberg EM, Rettenbacher M, et al. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. Lancet Psychiatry. 2020;7:945–54.

    PubMed  Google Scholar 

  • Kahn RS, Fleischhacker WW, Boter H, Davidson M, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–97.

    CAS  PubMed  Google Scholar 

  • Kogeorgos J, Kanellos P, Michalakeas A, Ioannidis J. Sulpiride and risperidone vs. “classical neuroleptics” in schizophrenia: a follow-up study. Eur Neuropsychopharmacol. 1995;5:335–6.

    Google Scholar 

  • Komossa K, Rummel-Kluge C, Hunger H, Schmid F, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD006624.

    Google Scholar 

  • Krause M, Zhu Y, Huhn M, Schneider-Thoma J, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268:625–39.

    PubMed  Google Scholar 

  • Lai EC, Chang CH, Kao Yang YH, Lin SJ, Lin CY. Effectiveness of sulpiride in adult patients with schizophrenia. Schizophr Bull. 2013;39:673–83.

    PubMed  Google Scholar 

  • Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disord. 1997;43:95–103.

    CAS  PubMed  Google Scholar 

  • Lecrubier Y, Azorin M, Bottai T, Dalery J, et al. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology. 2001;44:41–6.

    CAS  PubMed  Google Scholar 

  • Lepola U, Koskinen T, Rimón R, Salo H, Gordin A. Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. Acta Psychiatr Scand. 1989;80:92–6.

    CAS  PubMed  Google Scholar 

  • Leucht S, Cipriani A, Spineli L, Mavridis D, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.

    CAS  PubMed  Google Scholar 

  • Levine M, Ruha AM. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. CNS Drugs. 2012;26:601–11.

    CAS  PubMed  Google Scholar 

  • Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry. 1997;170:18–22.

    CAS  PubMed  Google Scholar 

  • Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V. Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics. Eur J Pharmacol. 1994;256:211–4.

    CAS  PubMed  Google Scholar 

  • Malm H, Folk ME, Lahesmaa-Korpinen A-M. Safety of the second generation antipsychotics during pregnancy. Reprod Toxicol. 2018;80:149–50.

    Google Scholar 

  • McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs. 2004;18:933–56.

    CAS  PubMed  Google Scholar 

  • Möller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacolgy. 1997;132:396–401.

    Google Scholar 

  • Munk-Andersen E, Behnke K, Heltberg J, Nielsen H, Gerlach J. Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatr Scand Suppl. 1984;311: 31–41.

    Google Scholar 

  • Niskanen P, Tammninen T, Viukari M. Sulpiride vs. amitriptyline in the treatment of depression. Curr Ther Res. 1975;17:281–4.

    CAS  PubMed  Google Scholar 

  • Noble S, Benfield P. Amisulpride: a review of its clinical potential in dysthymia. CNS Drugs. 1999;12:471–83.

    CAS  Google Scholar 

  • Nuss P, Hummer M, Tessier C. The use of amisulpride in the treatment of acute psychosis. Ther Clin Risk Manag. 2007;3:3–11.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Pagsberg AK, Tarp S, Glintborg D, Stenstrøm AD, et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adoles Psychiatry. 2017;56:191–202.

    Google Scholar 

  • Pani L, Gessa GL. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry. 2002;7:247–53.

    CAS  PubMed  Google Scholar 

  • Peuskens J, Bech P, Möller HJ, Bale R, et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res. 1999;88:107–17.

    CAS  PubMed  Google Scholar 

  • Peuskens J, Möller HJ, Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol. 2002;12:305–10.

    CAS  PubMed  Google Scholar 

  • Pillinger T, McCutcheon RA, Yuya Mizuno VL, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77.

    Google Scholar 

  • Rama Rao VA, Bailey J, Bishop M, Coppen A. A clinical and pharmacodynamics evaluation of sulpiride. Psychopharmacology. 1981;73:77–80.

    Google Scholar 

  • Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280:83–97.

    CAS  PubMed  Google Scholar 

  • Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47:43–52.

    CAS  PubMed  Google Scholar 

  • Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study. J Affect Disord. 1998;48:47–56.

    CAS  PubMed  Google Scholar 

  • Standish-Barry HM, Bouras N, Bridges PK, Watson JP. A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder. Psychopharmacology. 1983;81:258–60.

    CAS  PubMed  Google Scholar 

  • Wang J, Sampson S. Sulpiride versus placebo for schizophrenia. Cochrane Database Syst Rev. 2014;4:CD007811.

    Google Scholar 

  • Wetzel H, Gründer G, Hillert A, Philipp M, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology – a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology. 1998;137:223–32.

    CAS  PubMed  Google Scholar 

  • Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16:1205–18.

    CAS  PubMed  Google Scholar 

  • Zhu Y, Krause M, Huhn M, Rothe P, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017;4:694–705.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

  2. MVZ Waldkraiburg, Center of Neuropsychiatry, Waldkraiburg, Germany

    Gerd Laux

  3. Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University (LMU), Munich, Germany

    Gerd Laux

Authors
  1. Gerd Laux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerd Laux .

Editor information

Editors and Affiliations

  1. Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, Wuerzburg, Germany

    Peter Riederer

  2. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

  3. Centre for Research Promotion and Support, Fujita Health University, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Germany

    Christian Riederer

Section Editor information

  1. Department of Psychiatry, University Hospital Leipzig, Leipzig, Germany

    Frank Schmidt

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Laux, G. (2022). Amisulpride and Sulpiride in the Treatment of Psychosis. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_57

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62059-2_57

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62058-5

  • Online ISBN: 978-3-030-62059-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation